Monday, April 14, 1997
WASHINGTON - Fragments
of RNA and DNA, including Expressed Sequence Tags (ESTs), may be patented but
such patents are not likely to have a negative impact on subsequent efforts to
patent the entire gene, according to a letter written to NIH Director Harold
Varmus by Patent Commissioner Bruce Lehman.
supports comments made to BioCentury last week by John Doll, head of the
biotechnology group at the Patent and Trademark Office (PTO), in which Doll
indicated that the first patents on ESTs may be issued in a few months (see
BioCentury, April 7).